Marc Hedrick | President and Chief Executive Officer |
Tiago Girão | Vice President of Finance and Chief Financial Officer |
Jason Kolbert | H.C. Wainwright |
Jason McCarthy | Maxim |
Andrew D’Silva | B. Riley FBR |
I-Eh Jen | Laidlaw & Company |
Good afternoon, ladies and gentlemen. Welcome to Cytori Therapeutics First Quarter 2018 Earnings Results Call. At this time, all participants have been placed in a listen-only mode and the floor will be opened for questions following the presentation. [Operator Instructions] Before we begin, we want to advise you that over the course of the call and question-and-answer session, forward-looking statements will be made regarding events, trends, business prospects and financial performance, which may affect Cytori’s future operating results and financial position. All such statements are subject to risks and uncertainties, including the risks and uncertainties described under the Risk Factors section included in Cytori’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission from time to time.